DDAVP: does the drug have a direct effect on the vessel wall?
Evidence is presented that 1-deamino-8-d-arginine vasopressin (DDAVP), a vasopressin analog, has a direct effect on isolated vessel segments. The most significant finding is increased platelet adhesion and spreading at injury sites. An isologous human umbilical vein perfusion model was used to compare effects of DDAVP with those of epinephrine or zero drug controls. Scanning electron microscopy, in conjunction with morphometry, permitted quantification of platelet adhesion to subendothelium exposed by minimal injury in the model. In addition, umbilical vein effluents were tested for levels of factor VIII moieties (F VIII:C, F VIII:Rag, F VIII:RCof) and the prostanoids, 6 keto PGF1 alpha (stable metabolite of prostacyclin) and TXB2 (stable metabolite of thromboxane A2. Only F VIII:C from DDAVP treated segments was significantly (p less than 0.01) changed from controls.
D015121:6-Ketoprostaglandin F1 alpha / Q000032:analysis; D000941:Antigens / Q000032:analysis; D001127:Arginine Vasopressin / Q000494:pharmacology*; D001808:Blood Vessels / Q000187:drug effects*; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology*; D004837:Epinephrine / Q000494:pharmacology; D005169:Factor VIII / Q000032:analysis / Q000276:immunology; D006801:Humans; D066298:In Vitro Techniques; D008855:Microscopy, Electron, Scanning; D010477:Perfusion; D010973:Platelet Adhesiveness / Q000187:drug effects; D013929:Thromboxane B2 / Q000032:analysis; D014471:Umbilical Veins / Q000187:drug effects / Q000648:ultrastructure; D014841:von Willebrand Factor
D000941:Antigens; D014841:von Willebrand Factor; D001127:Arginine Vasopressin; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin; D004837:Epinephrine